Drugs / Lipovaxin-MM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01052142 | Sep 2009 → Mar 2012 | melanoma | Lipotek Pty Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lipovaxin-MM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01052142 ↗ |
| Modality | Vaccine | “Lipovaxin-MM, a new anti-cancer vaccine” NCT01052142 ↗ |
| Route | Intravenous | “Patients will receive three doses of Lipovaxin-MM by intravenous infusion at intervals of four weeks OR patients will receive 4 doses of Lipovaxin-MM by intravenous infusion at...” NCT01052142 ↗ |